Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCab trial of cabazitaxel with or without rhenium-188 HEDP in metastatic castration-resistant prostate cancer
NL-OMON44670Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel and Rhenium-188-HEDP in prostate cancer (PCa) and bone metastases (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Dose-limiting toxicity and Progression-free survival. Started Jun 2016; status: recruiting.
02
Drugs
cabazitaxelRhenium-188-HEDP
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on NL-OMON44670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44670.